Eli Lilly to Supply 150,000 More Doses of Bebtelovimab to U.S. Government

Eli Lilly will supply an additional 150,000 doses of its monoclonal antibody COVID-19 drug, bebtelovimab, to the U.S. government for approximately $275 million.

The FDA granted bebtelovimab Emergency Use Authorization on June 16 for treatment of mild-to-moderate COVID-19 in adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (88.2 pounds) who are at high risk for progressing to severe COVID-19 and have no other valid treatment options.

The company said the delivery of the additional doses will begin immediately and will be completed no later than August 5.

“While Congress works toward additional COVID-19 funding, Lilly and the U.S. government will continue to work together to support the availability of bebtelovimab,” said Lilly’s CEO David A. Ricks.